In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol^® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.

Grippol^® Quadrivalent will be manufactured in Russia full-cycle starting from API production to the applicable GMP regulations. The vaccine will be preservative-free and will be released in single-dose syringes.
The key benefit of the Russian quadrivalent vaccine is a high efficacy with a low reactogenicity.

Only six countries manufacture quadrivalent vaccines on their own, including Australia, the USA, Canada, New Zealand, Germany, and France. Russia is the 7th country that has independent vaccine production capacities.

For more information follow the link http://petrovax.com/press_centre/news/2018/1344/